Company Profile

Structured around aiding the development of new medicines by enabling cutting edge science and cross–disciplinary collaborations, New Equilibrium Biosciences is leveraging the firm's computational–experimental platform to discover potential drug candidates having the capacity to regulate intrinsically disordered proteins (IDP) implicated in cancers and neurodegenerative disorders. Combining big data, artificial intelligence, and biophysical experiments effectively to freeze-frame IDPs enables an accurately visualization of the ensemble of different conformations that an IDP adopts. This 3D structural information offers the potential to design and optimize drugs targeting IDPs using structure-based drug design methods. Objective: identify rug malfunctioning IDPs and restore normal cellular function. The approach is to employ bioinformatics and mutagenesis assays to identify the functional roles of individual IDP states - then to compare the set of conformations adopted by a “wild-type” protein in healthy cells and those from an impaired form of the protein in diseased cells. By targeting onl the pathogenic conformations in diseased cells, the healthy protein remains unimpaired, - offering the potential of a new route to low-toxicity drugs. The firm's platform is solidly anchored in the cross-disciplinary insights from a range of disciplines: physics, chemistry, mathematics, computer science, biophysics, and cell bi